TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05618327
Drug: JS203 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter.
Study: NCT06314256
Drug: Injection
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdental papilla will be injected by Tesoyal PureSense Glabal Action HA gel.
Study: NCT06256445
Drug: Polyene Phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL
Study: NCT06256445
Drug: Matching placebo of AYP-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT04496674
Drug: CC-1 and Toczilizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adminsitration of CC-1 and Toczilizumab
Study: NCT05351905
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Study: NCT00005024
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005024
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05058404
Drug: Immunochemotherapy regimen: R-CHOP (Arm B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis.
Study: NCT05583240
Drug: Essences and Essential Oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will received Essential Oils through a nasal stick during 4 weeks.
Study: NCT05058404
Drug: Immunochemotherapy regimen: G-CHOP (Arm A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion.
Study: NCT05058404
Drug: Immunochemotherapy regimen: G-CHOP (Arm B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion.
Study: NCT04703764
Drug: HSG4112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, 14-day multiple oral administration
Study: NCT04703764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, 14-day multiple oral administration
Study: NCT00378781
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin flush solution into CVC once daily.
Study: NCT00378781
Drug: Minocycline-EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-EDTA flush solution into CVC once daily.
Study: NCT04857892
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be administered via oral route.
Study: NCT04857892
Drug: GSK3640254/DTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254/DTG will be administered via oral route.
Study: NCT04853199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
Study: NCT04639024
Drug: ADCT-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
Study: NCT06500234
Drug: Starch powder 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch powder 50 mg, oral, everyday
Study: NCT05349097
Drug: SAD Placebo 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive a single oral dose of 30mg matching placebo
Study: NCT05349097
Drug: SAD Placebo 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive a single oral dose of 100mg matching placebo
Study: NCT05349097
Drug: SAD Placebo 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive a single oral dose of 200mg matching placebo
Study: NCT05349097
Drug: SAD Placebo 400mg
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive a single oral dose of 400mg matching placebo
Study: NCT05349097
Drug: SAD Placebo 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive a single oral dose of 600mg matching placebo
Study: NCT05349097
Drug: MAD IMG-004 50mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
Study: NCT05349097
Drug: MAD Placebo 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
Study: NCT05349097
Drug: MAD IMG-004 150mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
Study: NCT05349097
Drug: MAD Placebo 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
Study: NCT05349097
Drug: MAD IMG-004 300mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
Study: NCT05349097
Drug: MAD Placebo 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
Study: NCT06090565
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Four 500 mg tablets will be administered orally to equal a 2 g dose.
Study: NCT05536570
Drug: IncobotulinumtoxinA 100 UNT
Normalized name: incobotulinumtoxinA 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalene injection
Study: NCT05045872
Drug: domestic polysaccharide superparamagnetic iron oxide nanoparticle
Normalized name: iron oxide, nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
Study: NCT06027151
Drug: 1ml of 2% minocycline gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml of 2% minocycline gel sub gingivally at baseline visit
Study: NCT06027151
Drug: 1ml of combination of 1% metronidazole gel and 2% minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml of the combination of 1% metronidazole gel and 2% minocycline subgingivally at baseline visit
Study: NCT05132218
Drug: Ensatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective, exploratory, single-arm, multi-center, real-world research
Study: NCT05822180
Drug: NANOS1 , argent colloïdal ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, during 5 day
Study: NCT05653037
Drug: RBD4059
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered RBD4059 in Healthy Subjects.
Study: NCT05653037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered Placebo in Healthys Subject.
Study: NCT06169982
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06009094
Drug: VC005 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 Placebo group with Local topical application
Study: NCT05236257
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for the patients from the eligible external cohorts.
Study: NCT05846373
Drug: Nicotinic Acid 500 MG Extended Release Oral Tablet
Normalized name: nicotinic acid 500 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinic acid 500 mg for 12 weeks
Study: NCT05846373
Drug: Nicotinic Acid 1000 MG Extended Release Oral Tablet
Normalized name: nicotinic acid 1000 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
Study: NCT06437639
Drug: Mexidol
Normalized name: Brexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocytoprotector
Study: NCT06185400
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
Study: NCT05401916
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
Study: NCT06214468
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collection of urine at different time intervals following ingestion of Tylenol only
Study: NCT05987696
Drug: CD33/CLL1 dual CAR-NK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell therapy
Study: NCT05987696
Drug: super NK cell
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell therapy
Study: NCT05390476
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg orally three times a day (continuously)
Study: NCT00000768
Drug: Glutamic acid hydrochloride
Normalized name: Glutamic acid hydrochloride
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05038787
Drug: LY3473329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05038787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04701190
Drug: Noradrenaline 0.1 microgram/kg/minute infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Study: NCT04701190
Drug: Noradrenaline 0.05 microgram/kg/minute infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Study: NCT05487261
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
Study: NCT05487261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
Study: NCT05320536
Drug: Guilingji Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medicine is capsule medicine, take method is oral.
Study: NCT05320536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medicine is capsule medicine（Placebo）, take method is oral.
Study: NCT04816890
Drug: M1 Pram P037
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
Study: NCT05532813
Drug: Treatment taken
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
Study: NCT06243640
Drug: Buagafuran capsules, 15mg/ capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
Study: NCT06243640
Drug: Buagafuran capsules mimic, 0mg/ capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
Study: NCT06362317
Drug: Gemox Chemotherapy（Gemox or GC）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1.
Study: NCT05818306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04569760
Drug: 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabinoid oil preparation dosed in 1ml increments
Study: NCT04569760
Drug: Placebo Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
Study: NCT05727735
Drug: Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
Study: NCT06066606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are administered placebo
Study: NCT05549297
Drug: Investigators Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators choice of therapy
Study: NCT06322017
Drug: Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations.
Study: NCT04696250
Drug: Antineoplastic and Immunomodulating Agents
Normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
Study: NCT04478305
Drug: Duavive 0.45Mg-20Mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duavee, marketed as Duavive in Canada.
Study: NCT06377228
Drug: Chemotherapy Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and cyclophosphamide as per standard of care.
Study: NCT05969730
Drug: Azathioprine 1.5-2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm B). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
Study: NCT04814121
Drug: Suxiao Jiuxin Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
Study: NCT04814121
Drug: The placebo of Suxiao Jiuxin Pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
Study: NCT04729296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Drug
Study: NCT04990219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - capsule
Study: NCT05061524
Drug: YH35324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of YH35324
Study: NCT05061524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of None of active ingredient
Study: NCT05230472
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 60 mg tab
Study: NCT04771273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04758897
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
Study: NCT05128305
Drug: traditional Chinese medicine1 and traditional Chinese medicine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
Study: NCT06141577
Drug: UIC202201
Approvals — FDA: no, EMA: no, PMDA: no
Description: take UIC202201 1cap/day for 7 days
Study: NCT05268198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06108219
Drug: Placebo (Cohort A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for oral dosing for 48 Weeks
Study: NCT06108219
Drug: Placebo (Cohort B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for oral dosing for 24 Weeks
Study: NCT05376189
Drug: Fixed Drug Combination
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
Study: NCT05566028
Drug: D745 formulation I
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Study: NCT05566028
Drug: D745 formulation II
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Study: NCT05566028
Drug: D745 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Study: NCT06492356
Drug: medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty patients will receive medical treatment by dermatologist.
Study: NCT05541757
Drug: In vitro heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro heparin and in vitro LMWH